Cais Rhyddid Gwybodaeth / Freedom of Information request
Ein Cyf / Our Ref: 23-F-006

Please note we have provided data below for the 3 month period – February to April 2023.

You asked:

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- **Adalimumab – Humira** - 11
- **Adalimumab Biosimilar** - 123
- **Filgotinib** - <5*
- **Golimumab** - 0
- **Infliximab – Remicade** – <5* (3 additional units were supplied to award as ward stock. We are not able to say how many patients were treated with ward stock.)
- **Infliximab Biosimilar** – 15 (1 additional unit was supplied to a ward as ward stock. We are not able to say how many patients were treated with ward stock.)
- **Ozanimod** - 0
- **Tofacitinib** - <5*
- **Upadacitinib** <5*
- **Ustekinumab** - 78
- **Vedolizumab** – 129 (7 additional were supplied to ward)
- **Vedolizumab Injections ONLY (pre-filled pens or syringes)** – 8

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

This information is via the Homecare pharmacy system only. Information is not held centrally for all patients, therefore to obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees)

Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

- **Adalimumab – Humira** - 5
- **Adalimumab Biosimilar** - 35
- **Filgotinib** <5*
- **Golimumab** - 0
- **Infliximab – Remicade** - 0
- **Infliximab Biosimilar** – 2
- **Ozanimod** - 0
- **Tofacitinib** <5*
- **Upadacitinib** <5*
- **Ustekinumab** - 19
- **Vedolizumab** - 5
- **Vedolizumab Injections ONLY (pre-filled pens or syringes)** <5*

Q3. Does your Health Board participate in clinical trials for the treatment of Ulcerative Colitis? If so, please provide the total number of patients taking part in any Ulcerative Colitis study.

Yes, 270 patients were enrolled in studies.

*Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.
